Orrick Advises Rafael Pharmaceuticals on Merger with Rafael Holdings
| June.21.2021
Orrick is advising Rafael Pharmaceuticals, a clinical-stage oncology company, on its proposed merger with Rafael Holdings.
Helping life
sciences
companies
innovate
and grow
Life Sciences Sector
Our Life Sciences practice is built around our core commitment to support the development of technology that improves lives.
Client Results
Orrick Advises SOC Telemed on $194 Million Acquisition of Access Physicians
| March.31.2021
This combination furthers SOC Telemed's position as the largest pure-play provider of acute care telemedicine in the nation.
Orrick Team Obtains Landmark Referral to EU Top Court for Roche in Italian Pharma Antitrust Dispute
| March.30.2021
Our Italy team is advising Roche in a high-profile case at the intersection of competition law and pharmaceutical sector regulation.
Orrick Advises GuideTx on Acquisition by Beam Therapeutics
| February.23.2021
We advised Guide Therapeutics, a developer of nonviral drug delivery vehicles for genetic medicines, on its acquisition by biotech company Beam ...
International Arbitration Team Secures Major Win for Pioneering Swiss Non‐Profit Research Foundation EspeRare
| January.29.2021
The outcome validated EspeRare’s rescission, on grounds of fraud in the inducement, of an R & D collaboration agreement.
Orrick Advises Catalyst Biosciences on Underwritten Public Offering
| January.27.2021
Congratulations to Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company, on its underwritten public offering.
Orrick Advises K Health on $132 Million Series E Round
| January.20.2021
Congratulations to our healthcare technology client K Health on its $132 million Series E financing round.
Orrick Advises Aledade on $100 Million Series D
| January.19.2021
Orrick congratulates healthcare technology client Aledade on its $100 million Series D financing round.
Orrick Advises Swoop on Acquisition by W2O
| January.08.2021
Orrick has advised AI solutions provider Swoop on its acquisition by global health innovation company W2O.
Orrick Advises VNV Global on Its Investment in Babylon’s $100 Million Financing
| December.17.2020
We have advised VNV Global on its investment in digital healthcare service provider Babylon’s $100 million financing round.
Insights
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2021
| April.20.2021
Record-breaking Markets and a Candid Conversation on University Spinouts
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2021
| February.01.2021
We review full-year 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector.
Using M&A Insurance on Tech Deals (Issue 3): Fintech, edtech and healthtech/medtech
by Peter M. Lamb, David M. Ruff, Hari Raman, Daniel Lopez and Zac Padgett | January.21.2021
We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q3 2020
| October.22.2020
Venture Surges and the Rise of SPACs
In this edition, the traditional update on broader venture market financing data is included.
In this edition, the traditional update on broader venture market financing data is included.
Investments in Germany under COVID 19 – Turning a Crisis into Opportunities
by Dr. Oliver Duys LL.M. (UNSW Sydney), Abhijit Narayan and Hayat Makhloufi | August.17.2020
This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q2 2020
| August.10.2020
Companies & Investors Navigate the Pandemic Era
In this new series, we explore trends in venture investing across the life sciences sector.
In this new series, we explore trends in venture investing across the life sciences sector.
China Proposes to Tighten Biosecurity Law and its Potential Impact on Foreign Pharmaceutical and Biotech Companies Operating in China
by Betty L. Louie, Yufeng (Ethan) Ma and Martha Wang | July.10.2020
On April 26, 2020, the Standing Committee of the National People's Congress, China’s top legislature, passed the second draft of the country’s ...
Board Oversight of Clinical Trials During the Pendency of the COVID-19 Pandemic
by Albert Vanderlaan and Stephen Thau | June.19.2020
COVID-19 has had far-reaching social, economic and regulatory impacts. Nearly all companies (private and public, large and small) have had reason to ...
Direct Listings May Pose Challenges for Cash Intensive Life Sciences Companies
by Albert Vanderlaan | May.14.2020
Are direct listings a viable potential alternative for all companies seeking to go public? The answer may likely be no.
Managing and Maintaining Clinical Trial Disclosure for Publicly Traded Life Sciences Companies
by Albert Vanderlaan | May.21.2020
The following discussion is intended to help guide companies in making clinical trial-related disclosures.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2020
| May.11.2020
The Market Meets COVID-19
In this new series, we explore trends in venture investing across the life sciences sector.
In this new series, we explore trends in venture investing across the life sciences sector.
Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical Biology
by Marie-Laure Combet and Elise Durand | April.26.2019
On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical ...
Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company
| February.21.2019
Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...
Scope of Estoppel Post-IPR Proceedings Becoming Clearer
by K. Patrick Herman | March.27.2017
This estoppel provision has been the subject of a number of Federal Circuit and district court decisions.
HALLOWEEN TREAT: Judge’s October 31 Order Adds $21 Million to Jury’s $70 Million Award for Trade Secret Theft
by Mona S. Amer | November.22.2016
On October 31st of this year, a district judge in Massachusetts granted a motion for enhanced damages in a theft of trade secrets case, adding an ...
News
Orrick Adds Patent Prosecution Leader to Fast Growing Life Sciences Team
| March.15.2021
Gargi Talukder, a recognized leader in protecting the innovations of life sciences companies, has joined the firm as a partner in San Francisco.
Orrick Adds Life Sciences Authority David Schulman
| January.25.2021
Orrick announced today that premier life sciences advisor David Schulman has joined the firm as a partner in Washington, D.C.
Orrick Adds Life Sciences Licensing Advisor Shana Solomon
| September.09.2020
Orrick announced today that Shana Solomon, a seasoned advisor to companies in the life science, biotechnology and pharmaceutical industries, has ...
Antitrust Watch Blog
In-depth analysis and commentary on major developments in global antitrust and competition law
The World in U.S. Courts
A quarterly review of the most important decisions applying U.S. law to global business and cross-border activities.
Some of the recognition we have received
IP Group of the Year
Law360, 4 times
Tech Group of the Year
Law360, 2018 and 3 times
Employment Group of the Year
Law360, 2020 and 5 times
Recommended
Global Competition Review 100, 2019
IP Litigation Department of the Year
The American Lawyer, 2016
Top 5 Litigation Powerhouse
Law360, 2016
Litigation Power Rankings – Top 10
The American Lawyer, 2016
Appellate Hot List
National Law Journal, 2020 and 9 times
Litigation Department of the Year
The Recorder, 2016 and 2 times
Labor & Employment Defense Firm of the Year
The Recorder, 2017 and 4 times
International IP Firm of the Year
China Law & Practice, 2015
Tier 1 for China Patent Work
Asian Legal Business, 2013-2018
China Foreign Law Firm of the Year
Managing IP, 2016